NASDAQ$MGTX
MeiraGTx Holdings plc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
MeiraGTx reported Q3 2025, revenue of $410K, net loss of $50.5M.
For Q3 2025, MeiraGTx reported revenue of $410K, a net loss of $50.5M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Revenue $410K.
- Net loss $50.5M.
- MeiraGTx MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
MeiraGTx · Revenue · Quarterly
$410K
Forward guidance
Clinical-stage biotech outlook centers on trial readouts, cash runway, and partnership optionality.
Tailwinds
- Pipeline milestones and enrollment.
- Collaboration or licensing potential.
- Non-dilutive funding paths.
Headwinds
- Trial failure or delay risk.
- Burn rate and dilution.
- Regulatory and competitive landscape.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
+0.1%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.0%
Avg return
30 days after
31%
10 / 32 earnings
Positive
+25.0%
Q1 2019
Best reaction
-20.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -6.1% | — | |
| Q1 2026 | -0.2% | -8.4% | -3.7% | |
| Q3 2025 | -4.5% | -10.5% | +3.0% | |
| Q2 2025 | -0.1% | -9.1% | -8.8% | |
| Q1 2025 | -0.4% | +5.2% | +31.5% | |
| Q4 2024 | +1.3% | +17.0% | -18.9% | |
| Q3 2024 | -0.3% | -8.6% | -8.1% | |
| Q2 2024 | -3.4% | -3.2% | -4.8% | |
| Q1 2024 | -1.4% | +1.8% | -7.2% | |
| Q4 2023 | +0.0% | -1.1% | -12.4% | |
| Q3 2023 | +4.7% | +19.2% | -1.3% | |
| Q2 2023 | +5.6% | +1.6% | -3.8% | |
| Q1 2023 | -6.9% | +12.9% | +30.2% | |
| Q4 2022 | -3.4% | -11.9% | -8.3% | |
| Q3 2022 | -7.3% | -6.3% | -13.2% | |
| Q2 2022 | +14.4% | +7.0% | -5.9% | |
| Q1 2022 | -3.1% | -5.9% | -15.0% | |
| Q4 2021 | -2.4% | -5.0% | -7.1% | |
| Q3 2021 | -1.7% | -1.7% | +1.8% | |
| Q2 2021 | -0.9% | -8.3% | -16.2% | |
| Q1 2021 | -2.4% | -3.7% | +10.2% | |
| Q4 2020 | +8.0% | +9.1% | -17.3% | |
| Q3 2020 | -1.7% | +4.1% | -6.9% | |
| Q2 2020 | +5.1% | +5.6% | -3.7% | |
| Q1 2020 | +7.8% | +16.1% | +8.0% | |
| Q4 2019 | -20.4% | -38.8% | -11.1% | |
| Q3 2019 | +1.7% | +6.7% | +49.4% | |
| Q2 2019 | -10.6% | -15.2% | -22.9% | |
| Q1 2019 | +25.0% | +32.1% | +23.5% | |
| Q4 2018 | -3.0% | -3.7% | +3.4% | |
| Q3 2018 | -2.6% | -5.3% | -5.5% | |
| Q2 2018 | +7.9% | +6.2% | +40.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro